Yonghe Zhikong recently announced its intention to transfer 100% of its equity stake in Kunming Medical Co., Ltd. This move signifies the company’s strategic realignment to refocus on its core business and optimize its asset structure. Kunming Medical, previously a key platform for Yonghe Zhikong’s foray into the healthcare sector, has made certain regional progress in medical services since its acquisition. However, due to evolving industry regulations and rising operational costs, its profitability has fallen short of expectations. By divesting this asset, Yonghe Zhikong aims to recover capital, concentrate resources on its core fluid control equipment manufacturing operations, and reduce management and financial risks associated with diversified business lines. According to the announcement, the buyer is a professional investment institution with a background in the healthcare industry, though specific transaction terms and closing arrangements remain subject to further negotiation. Market analysts view this decision as aligned with the broader trend among Chinese manufacturers to ‘return to core operations,’ which could enhance the company’s long-term competitiveness and shareholder returns.Yonghe Zhikong stated that the equity transfer will not significantly impact its normal business operations, and the transaction remains subject to internal approvals and regulatory clearance. The company will continue evaluating its portfolio efficiency to support high-quality, sustainable growth.
永和智控（Yonghe Zhikong）近日宣布，拟将其持有的昆明医科有限公司100%股权转让。此次交易标志着公司进一步聚焦主营业务、优化资产结构的战略调整。昆明医科作为永和智控此前布局医疗健康领域的重要平台，自收购以来在区域医疗服务方面取得一定进展，但受行业政策变化及运营成本上升等因素影响，整体盈利表现未达预期。通过本次股权转让，永和智控有望回笼资金，集中资源发展其核心的流体控制设备制造业务，并降低多元化经营带来的管理与财务风险。公告显示，交易对方为具备医疗产业背景的专业投资机构，具体交易对价及交割安排尚待双方进一步协商确定。市场分析人士认为，此举符合当前制造业企业‘回归主业’的整体趋势，有助于提升公司长期竞争力与股东回报。永和智控表示，本次股权转让不会对公司正常生产经营造成重大影响，相关事项尚需履行内部决策程序及监管审批。未来，公司将持续评估资产组合效率，推动高质量可持续发展。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/11259.html